BioMarin CBO James Sabry at #JPM24 (Brian Benton Photography)
BioMarin turns to ex-Roche dealmaker James Sabry to build ‘next version’ of 27-year-old company
SAN FRANCISCO — Not many biotechs survive beyond 25 years, let alone get multiple drugs approved and turn a profit.
BioMarin Pharmaceutical has done all …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
